IgG4-related sclerosing cholangitis, a biliary manifestation of an IgG4-related disease, belongs to the spectrum of sclerosing cholangiopathies which result in biliary stenosis. It presents with signs of cholestasis and during differential diagnosis it should be distinguished from cholangiocarcinoma or from other forms of sclerosing cholangitis (primary and secondary sclerosing cholangitis). Despite increasing information and recently established diagnostic criteria, IgG4-related sclerosing cholangitis remains underdiagnosed in routine clinical practice. The diagnosis is based on a combination of the clinical picture, laboratory parameters, histological findings, and a cholangiogram. Increased serum IgG4 levels are nonspecific but are indeed a part of the diagnostic criteria proposed by the Japan Biliary Association and the HISORt criteria for IgG4-SC. High serum IgG4 retains clinical utility depending on the magnitude of elevation. Approximately 90% of patients have concomitant autoimmune pancreatitis, while 10% present with isolated biliary involvement only. About 26% of patients have other organ involvement, such as IgG4-related dacryoadenitis/sialadenitis, IgG4-related retroperitoneal fibrosis, or IgG4-related renal lesions. A full-blown histological finding characterized by IgG4-enriched lymphoplasmacytic infiltrates, obliterative phlebitis, and storiform fibrosis is difficult to capture in practice because of its subepithelial localization. However, the histological yield is increased by immunohistochemistry, with evidence of IgG4-positive plasma cells. Based on a cholangiogram, IgG-4 related sclerosing cholangitis is classified into four subtypes according to the localization of stenoses. The first-line treatment is corticosteroids. The aim of the initial treatment is to induce clinical and laboratory remission and cholangiogram normalization. Even though 30% of patients have a recurrent course, in the literature data, there is no consensus on chronic immunosuppressive maintenance therapy. The disease has a good prognosis when diagnosed early.

Department of Gastroenterology Hepatology and Clinical Nutrition University of Zagreb School of Medicine and University Hospital Dubrava Avenija Gojka Suska 6 10000 Zagreb Croatia

Department of Infectology and Travel Medicine PJ Safarik University in Kosice and L Pasteur University Hospital Rastislavova 43 040 01 Kosice Slovakia

Department of Internal Medicine PJ Safarik University in Kosice and L Pasteur University Hospital Trieda SNP 1 040 11 Kosice Slovakia

Faculty of Medicine Charles University Katerinska 1660 32 121 08 Nove Mesto Prague Czech Republic

See more in PubMed

Deshpande V., Zen Y., Chan J. K., et al. Consensus statement on the pathology of igg4-related disease. Modern Pathology . 2012;25(9):1181–1192. doi: 10.1038/modpathol.2012.72. PubMed DOI

Umehara H., Okazaki K., Masaki Y., et al. Comprehensive diagnostic criteria for igg4-related disease (igg4-rd) Modern Rheumatology . 2012;22:21–30. PubMed

Zen Y., Harada K., Sasaki M., et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis. The American Journal of Surgical Pathology . 2004;28(9):1193–1203. doi: 10.1097/01.pas.0000136449.37936.6c. PubMed DOI

Ohara H., Okazaki K., Tsubouchi H., et al. Clinical diagnostic criteria of igg4-related sclerosing cholangitis 2012. Journal of Hepato-Biliary-Pancreatic Sciences . 2012;19(5):536–542. doi: 10.1007/s00534-012-0521-y. PubMed DOI

Kamisawa T., Funata N., Hayashi Y., et al. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis. Gut . 2003;52(5):683–687. doi: 10.1136/gut.52.5.683. PubMed DOI PMC

Okazaki K., Uchida K., Ikeura T., Takaoka M. Current concept and diagnosis of igg4-related disease in the hepato-bilio-pancreatic system. Journal of Gastroenterology . 2013;48(3):303–314. doi: 10.1007/s00535-012-0744-3. PubMed DOI PMC

Stone J. H., Khosroshahi A., Deshpande V., et al. Recommendations for the nomenclature of igg4-related disease and its individual organ system manifestations. Arthritis & Rheumatism . 2012;64(10):3061–3067. doi: 10.1002/art.34593. PubMed DOI PMC

Okazaki K., Kawa S., Kamisawa T., et al. Clinical diagnostic criteria of autoimmune pancreatitis: Revised proposal. Journal of Gastroenterology . 2006;41(7):626–631. doi: 10.1007/s00535-006-1868-0. PubMed DOI PMC

Yoshida K., Toki F., Takeuchi T., Watanabe S.-I., Shiratori K., Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Digestive Diseases and Sciences . 1995;40(7):1561–1568. doi: 10.1007/bf02285209. PubMed DOI

Kamisawa T., Nakajima H., Egawa N., Funata N., Tsuruta K., Okamoto A. Igg4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosis with lymphadenopathy. Pancreatology . 2006;6(1-2):132–137. doi: 10.1159/000090033. PubMed DOI

Ghazale A., Chari S. T., Zhang L., et al. Immunoglobulin g4-associated cholangitis: clinical profile and response to therapy. Gastroenterology . 2008;134(3):706–715. doi: 10.1053/j.gastro.2007.12.009. PubMed DOI

Hirano K., Tada M., Isayama H., et al. Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. Gastrointestinal Endoscopy . 2010;71(1):85–90. doi: 10.1016/j.gie.2009.08.008. PubMed DOI

Naitoh I., Kamisawa T., Tanaka A., et al. Clinical characteristics of immunoglobulin igg4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort. Digestive and Liver Disease . 2021;53(10):1308–1314. PubMed

Naitoh I., Nakazawa T., Ohara H., et al. Endoscopic transpapillary intraductal ultrasonography and biopsy in the diagnosis of igg4-related sclerosing cholangitis. Journal of Gastroenterology . 2009;44(11):1147–1155. doi: 10.1007/s00535-009-0108-9. PubMed DOI

Nakazawa T., Ikeda Y., Kawaguchi Y., et al. Isolated intrapancreatic igg4-related sclerosing cholangitis. World Journal of Gastroenterology . 2015;21(4):1334–1343. doi: 10.3748/wjg.v21.i4.1334. PubMed DOI PMC

Tanaka A., Tazuma S., Okazaki K., Tsubouchi H., Inui K., Takikawa H. Nationwide survey for primary sclerosing cholangitis and igg4-related sclerosing cholangitis in Japan. Journal of Hepato-Biliary-Pancreatic Sciences . 2014;21(1):43–50. doi: 10.1002/jhbp.50. PubMed DOI

Tanaka A. Igg4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut and Liver . 2019;13(3):300–307. doi: 10.5009/gnl18085. PubMed DOI PMC

Kanno A., Masamune A., Okazaki K., et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas . 2015;44(4):535–539. doi: 10.1097/mpa.0000000000000325. PubMed DOI

Kamisawa T., Nakazawa T., Tazuma S., et al. Clinical practice guidelines for igg4-related sclerosing cholangitis. Journal of Hepato-Biliary-Pancreatic Sciences . 2019;26(1):9–42. doi: 10.1002/jhbp.596. PubMed DOI PMC

Tanaka A., Mori M., Kubota K., et al. Epidemiological features of immunoglobulin G4‐related sclerosing cholangitis in Japan. Journal of Hepato-Biliary-Pancreatic Sciences . 2020;27(9):598–603. doi: 10.1002/jhbp.793. PubMed DOI

Tanaka A., Mori M., Matsumoto K., Ohira H., Tazuma S., Takikawa H. Increase trend in the prevalence and male‐to‐female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatology Research . 2019;49(8):881–889. doi: 10.1111/hepr.13342. PubMed DOI

Inoue D., Yoshida K., Yoneda N., et al. IgG4-Related disease. Medicine . 2015;94(15):p. e680. doi: 10.1097/md.0000000000000680. PubMed DOI PMC

Lin W., Lu S., Chen H., et al. Clinical characteristics of immunoglobulin g4-related disease: a prospective study of 118 Chinese patients. Rheumatology . 2015;54(11):1982–1990. doi: 10.1093/rheumatology/kev203. PubMed DOI

Chen Y., Zhao J.-Z., Feng R.-E., et al. Types of organ involvement in patients with immunoglobulin g4-related disease. Chinese Medical Journal . 2016;129(13):1525–1532. doi: 10.4103/0366-6999.184459. PubMed DOI PMC

Wallace Z. S., Deshpande V., Mattoo H., et al. Igg4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis & Rheumatology . 2015;67(9):2466–2475. doi: 10.1002/art.39205. PubMed DOI PMC

Campochiaro C., Ramirez G., Bozzolo E., et al. Igg4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scandinavian Journal of Rheumatology . 2016;45(2):135–145. doi: 10.3109/03009742.2015.1055796. PubMed DOI

Ebbo M., Daniel L., Pavic M., et al. IgG4-related systemic disease. Medicine . 2012;91(1):49–56. doi: 10.1097/md.0b013e3182433d77. PubMed DOI

Manganis C. D., Chapman R. W., Culver E. L. Review of primary sclerosing cholangitis with increased igg4 levels. World Journal of Gastroenterology . 2020;26(23):3126–3144. doi: 10.3748/wjg.v26.i23.3126. PubMed DOI PMC

Tanaka A., Tazuma S., Okazaki K., et al. Clinical features, response to treatment, and outcomes of igg4-related sclerosing cholangitis. Clinical Gastroenterology and Hepatology . 2017;15(6):920–926. doi: 10.1016/j.cgh.2016.12.038. PubMed DOI

Huggett M. T., Culver E. L., Kumar M., et al. Type 1 autoimmune pancreatitis and igg4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. American Journal of Gastroenterology . 2014;109(10):1675–1683. doi: 10.1038/ajg.2014.223. PubMed DOI PMC

Singh S., Talwalkar J. A. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clinical Gastroenterology and Hepatology . 2013;11(8):898–907. doi: 10.1016/j.cgh.2013.02.016. PubMed DOI PMC

Zhao E. J., Cheng C. V., Mattman A., Chen L. Y. C. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. The Lancet Haematology . 2021;8(5):e365–e375. doi: 10.1016/s2352-3026(21)00056-9. PubMed DOI

Khosroshahi A., Carruthers M. N., Deshpande V., Unizony S., Bloch D. B., Stone J. H. Rituximab for the treatment of igg4-related disease. Medicine . 2012;91(1):57–66. doi: 10.1097/md.0b013e3182431ef6. PubMed DOI

Okazaki K., Uchida K., Ohana M., et al. Autoimmune-related pancreatitis is associated with autoantibodies and a th1/th2-type cellular immune response. Gastroenterology . 2000;118(3):573–581. doi: 10.1016/s0016-5085(00)70264-2. PubMed DOI

Hubers L. M., Vos H., Schuurman A. R., et al. Annexin a11 is targeted by igg4 and igg1 autoantibodies in igg4-related disease. Gut . 2017;67(4):728–735. doi: 10.1136/gutjnl-2017-314548. PubMed DOI

Perugino C. A., AlSalem S. B., Mattoo H., et al. Identification of galectin-3 as an autoantigen in patients with igg4-related disease. The Journal of Allergy and Clinical Immunology . 2019;143(2):736–745. doi: 10.1016/j.jaci.2018.05.011. PubMed DOI PMC

Shiokawa M., Kodama Y., Sekiguchi K., et al. Laminin 511 is a target antigen in autoimmune pancreatitis. Science Translational Medicine . 2018;10 doi: 10.1126/scitranslmed.aaq0997. PubMed DOI

Aalberse R. C., Stapel S. O., Schuurman J., Rispens T. Immunoglobulin g4: an odd antibody. Clinical and Experimental Allergy . 2009;39(4):469–477. doi: 10.1111/j.1365-2222.2009.03207.x. PubMed DOI

Trampert D. C., Hubers L. M., van de Graaf S. F. J., Beuers U. On the role of igg4 in inflammatory conditions: lessons for igg4-related disease. Biochimica et Biophysica Acta - Molecular Basis of Disease . 2018;1864(4):1401–1409. doi: 10.1016/j.bbadis.2017.07.038. PubMed DOI

Hart P. A., Zen Y., Chari S. T. Recent advances in autoimmune pancreatitis. Gastroenterology . 2015;149(1):39–51. doi: 10.1053/j.gastro.2015.03.010. PubMed DOI

Nirula A., Glaser S. M., Kalled S. L., Taylora F. R. What is igg4? A review of the biology of a unique immunoglobulin subtype. Current Opinion in Rheumatology . 2011;23(1):119–124. doi: 10.1097/bor.0b013e3283412fd4. PubMed DOI

Okazaki K., Uchida K., Miyoshi H., Ikeura T., Takaoka M., Nishio A. Recent concepts of autoimmune pancreatitis and igg4-related disease. Clinical Reviews in Allergy and Immunology . 2010;41(2):126–138. doi: 10.1007/s12016-010-8214-2. PubMed DOI

Zen Y., Kawakami H., Kim J. H. Igg4-related sclerosing cholangitis: all we need to know. Journal of Gastroenterology . 2016;51(4):295–312. doi: 10.1007/s00535-016-1163-7. PubMed DOI

Grant C. R., Liberal R., Mieli-Vergani G., Vergani D., Longhi M. S. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmunity Reviews . 2015;14(2):105–116. doi: 10.1016/j.autrev.2014.10.012. PubMed DOI

Kleinewietfeld M., Hafler D. A. Regulatory t cells in autoimmune neuroinflammation. Immunological Reviews . 2014;259(1):231–244. doi: 10.1111/imr.12169. PubMed DOI PMC

Mattoo H., Della-Torre E., Mahajan V. S., Stone J. H., Pillai S. Circulating th2 memory cells in igg4-related disease are restricted to a defined subset of subjects with atopy. Allergy . 2014;69(3):399–402. doi: 10.1111/all.12342. PubMed DOI PMC

Della Torre E., Mattoo H., Mahajan V. S., Carruthers M., Pillai S., Stone J. H. Prevalence of atopy, eosinophilia, and ige elevation in igg4-related disease. Allergy . 2014;69(2):269–272. doi: 10.1111/all.12320. PubMed DOI PMC

Umehara H., Okazaki K., Masaki Y., et al. A novel clinical entity, igg4-related disease (igg4rd): general concept and details. Modern Rheumatology . 2011;22:1–14. PubMed PMC

Kawa S., Ota M., Yoshizawa K., et al. Hla drb1∗0405-dqb1∗0401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology . 2002;122(5):1264–1269. doi: 10.1053/gast.2002.33022. PubMed DOI

Park D. H., Kim M. H., Oh H. B., et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology . 2008;134(2):440–446. doi: 10.1053/j.gastro.2007.11.023. PubMed DOI

Culver E. L., Hurst J. M., Cargill T., et al. Human leucocyte antigen associations in igg4-related disease and primary sclerosing cholangitis stratified by igg4 levels, in a multicenter UK cohort. Journal of Hepatology . 2016;64(2):p. S646. doi: 10.1016/s0168-8278(16)01205-8. DOI

Chang M.-C., Chang Y.-T., Tien Y.-W., et al. T-cell regulatory gene ctla-4 polymorphism/haplotype association with autoimmune pancreatitis. Clinical Chemistry . 2007;53(9):1700–1705. doi: 10.1373/clinchem.2007.085951. PubMed DOI

Chang M.-C., Jan I.-S., Liang P.-C., et al. Human cationic trypsinogen but not serine peptidase inhibitor, kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis. Journal of Gastroenterology and Hepatology . 2014;29(12):2038–2042. doi: 10.1111/jgh.12649. PubMed DOI

Chang M.-C., Jan I.-S., Liang P.-C., et al. Cystic fibrosis transmembrane conductance regulator gene variants are associated with autoimmune pancreatitis and slow response to steroid treatment. Journal of Cystic Fibrosis . 2015;14(5):661–667. doi: 10.1016/j.jcf.2015.03.009. PubMed DOI

Umemura T., Ota M., Hamano H., Katsuyama Y., Kiyosawa K., Kawa S. Genetic association of fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut . 2006;55(9):1367–1368. doi: 10.1136/gut.2006.095059. PubMed DOI PMC

Umemura T., Ota M., Hamano H., et al. Association of autoimmune pancreatitis with cytotoxic t-lymphocyte antigen 4 gene polymorphisms in Japanese patients. American Journal of Gastroenterology . 2008;103(3):588–594. doi: 10.1111/j.1572-0241.2007.01750.x. PubMed DOI

Okazaki K., Uchida K., Koyabu M., Miyoshi H., Ikeura T., Takaoka M. IgG4 cholangiopathy - current concept, diagnosis, and pathogenesis. Journal of Hepatology . 2014;61(3):690–695. doi: 10.1016/j.jhep.2014.04.016. PubMed DOI

Muraki T., Hamano H., Ochi Y., et al. Autoimmune pancreatitis and complement activation system. Pancreas . 2006;32(1):16–21. doi: 10.1097/01.mpa.0000188308.75043.e4. PubMed DOI

Zen Y., Fujii T., Harada K., et al. Th2 and regulatory immune reactions are increased in immunoglobin g4-related sclerosing pancreatitis and cholangitis. Hepatology . 2007;45(6):1538–1546. doi: 10.1002/hep.21697. PubMed DOI

Ettinger R., Kuchen S., Lipsky P. E. Interleukin 21 as a target of intervention in autoimmune disease. Annals of the Rheumatic Diseases . 2008;67(Suppl 3):iii83–86. doi: 10.1136/ard.2008.098400. PubMed DOI

Maehara T., Moriyama M., Nakashima H., et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin g4 production in igg4-related dacryoadenitis and sialoadenitis, so-called mikulicz’s disease. Annals of the Rheumatic Diseases . 2012;71(12):2011–2020. doi: 10.1136/annrheumdis-2012-201477. PubMed DOI

Akiyama M., Suzuki K., Yamaoka K., et al. Brief report: number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease. Arthritis & Rheumatology . 2015;67(9):2476–2481. doi: 10.1002/art.39209. PubMed DOI

Miyoshi H., Uchida K., Taniguchi T., et al. Circulating naïve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas . 2008;36(2):133–140. doi: 10.1097/mpa.0b013e3181577553. PubMed DOI

Zen Y., Nakanuma Y. Pathogenesis of igg4-related disease. Current Opinion in Rheumatology . 2011;23(1):114–118. doi: 10.1097/bor.0b013e3283412f4a. PubMed DOI

Soler D., Chapman T. R., Poisson L. R., et al. Ccr8 expression identifies cd4 memory t cells enriched for foxp3+ regulatory and th2 effector lymphocytes. The Journal of Immunology . 2006;177(10):6940–6951. doi: 10.4049/jimmunol.177.10.6940. PubMed DOI

Zen Y., Liberal R., Nakanuma Y., Heaton N., Portmann B. Possible involvement of ccl1-ccr8 interaction in lymphocytic recruitment in igg4-related sclerosing cholangitis. Journal of Hepatology . 2013;59(5):1059–1064. doi: 10.1016/j.jhep.2013.06.016. PubMed DOI

Lanzillotta M., Della-Torre E., Milani R., et al. Increase of circulating memory b cells after glucocorticoid-induced remission identifies patients at risk of igg4-related disease relapse. Arthritis Research and Therapy . 2018;20(1):p. 222. doi: 10.1186/s13075-018-1718-5. PubMed DOI PMC

Lanzillotta M., Della-Torre E., Milani R., et al. Effects of glucocorticoids on b-cell subpopulations in patients with igg4-related disease. Clinical & Experimental Rheumatology . 2019;37(Suppl 118):159–166. PubMed

Perugino C. A., Stone J. H. Igg4-related disease: an update on pathophysiology and implications for clinical care. Nature Reviews Rheumatology . 2020;16(12):702–714. doi: 10.1038/s41584-020-0500-7. PubMed DOI

Wallace Z. S., Naden R. P., Chari S., et al. The 2019 american college of rheumatology/european league against rheumatism classification criteria for igg4-related disease. Annals of the Rheumatic Diseases . 2020;79(1):77–87. doi: 10.1136/annrheumdis-2019-216561. PubMed DOI

Nakazawa T., Kamisawa T., Okazaki K., et al. Clinical diagnostic criteria for IgG4‐related sclerosing cholangitis 2020. Journal of Hepato-Biliary-Pancreatic Sciences . 2021;28(3):235–242. doi: 10.1002/jhbp.913. PubMed DOI

Kawa S., Kamisawa T., Notohara K., et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: revision of Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011. Pancreas . 2020;49:e13–e14. PubMed PMC

Moon S.-H., Kim M.-H., Lee J. K., et al. Development of a scoring system for differentiating igg4-related sclerosing cholangitis from primary sclerosing cholangitis. Journal of Gastroenterology . 2017;52(4):483–493. doi: 10.1007/s00535-016-1246-5. PubMed DOI

Lanzillotta M., Campochiaro C., Mancuso G., et al. Clinical phenotypes of igg4-related disease reflect different prognostic outcomes. Rheumatology . 2020;59(9):2435–2442. doi: 10.1093/rheumatology/keaa221. PubMed DOI

Burak K., Angulo P., Pasha T. M., Egan K., Petz J., Lindor K. D. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. American Journal of Gastroenterology . 2004;99(3):523–526. doi: 10.1111/j.1572-0241.2004.04067.x. PubMed DOI

Hirano K., Tada M., Sasahira N., et al. Incidence of malignancies in patients with igg4-related disease. Internal Medicine . 2014;53(3):171–176. doi: 10.2169/internalmedicine.53.1342. PubMed DOI

Razumilava N., Gores G. J., Lindor K. D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology . 2011;54(5):1842–1852. doi: 10.1002/hep.24570. PubMed DOI PMC

Shiokawa M., Kodama Y., Yoshimura K., et al. Risk of cancer in patients with autoimmune pancreatitis. American Journal of Gastroenterology . 2013;108(4):610–617. doi: 10.1038/ajg.2012.465. PubMed DOI

Culver E. L., Sadler R., Simpson D., et al. Elevated serum igg4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective igg4-related disease UK cohort. American Journal of Gastroenterology . 2016;111(5):733–743. doi: 10.1038/ajg.2016.40. PubMed DOI

European Society of Gastrointestinal E. European Association for the Study of the Liver. Electronic address, e.e.e.; European Association for the Study of the, L. Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (esge) and european association for the study of the liver (easl) clinical guideline. Journal of Hepatology . 2017;66:1265–1281. PubMed

Lindor K. D., Kowdley K. V., Harrison E. M., American College of G. Acg clinical guideline: primary sclerosing cholangitis. American Journal of Gastroenterology . 2015;110(5):646–659. doi: 10.1038/ajg.2015.112. PubMed DOI

Alswat K., Al-Harthy N., Mazrani W., Alshumrani G., Jhaveri K., Hirschfield G. M. The spectrum of sclerosing cholangitis and the relevance of igg4 elevations in routine practice. American Journal of Gastroenterology . 2012;107(1):56–63. doi: 10.1038/ajg.2011.375. PubMed DOI

Benito de Valle M., Müller T., Björnsson E., et al. The impact of elevated serum igg4 levels in patients with primary sclerosing cholangitis. Digestive and Liver Disease . 2014;46(10):903–908. doi: 10.1016/j.dld.2014.06.010. PubMed DOI

Björnsson E., Chari S., Silveira M., et al. Primary sclerosing cholangitis associated with elevated ImmunoglobulinG4: clinical characteristics and response to therapy. American Journal of Therapeutics . 2011;18(3):198–205. doi: 10.1097/mjt.0b013e3181c9dac6. PubMed DOI

Boonstra K., Culver E. L., de Buy Wenniger L. M., et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4‐associated cholangitis from primary sclerosing cholangitis. Hepatology . 2014;59(5):1954–1963. doi: 10.1002/hep.26977. PubMed DOI PMC

Mendes F. D., Jorgensen R., Keach J., et al. Elevated serum igg4 concentration in patients with primary sclerosing cholangitis. American Journal of Gastroenterology . 2006;101(9):2070–2075. doi: 10.1111/j.1572-0241.2006.00772.x. PubMed DOI

Muir A. J., Levy C., Janssen H. L. A., et al. Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology . 2019;69(2):684–698. doi: 10.1002/hep.30237. PubMed DOI

Parhizkar B., Mohammad Alizadeh A. H., Asadzadeh Aghdaee H., Malekpour H., Entezari A. H. Primary sclerosing cholangitis associated with elevated immunoglobulin-g4: a preliminary study. ISRN Gastroenterology . 2012;2012:4. doi: 10.5402/2012/325743.325743 PubMed DOI PMC

Taghavi S. A., Majd S. K., Sianati M., Sepehrimanesh M. Prevalence of igg-4-associated cholangiopathy based on serum igg-4 levels in patients with primary sclerosing cholangitis and its relationship with inflammatory bowel disease. Turkish Journal of Gastroenterology . 2016;27(6):547–552. doi: 10.5152/tjg.2016.16344. PubMed DOI

Tanaka A., Tazuma S., Nakazawa T., et al. No negative impact of serum igg4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. Journal of Hepato-Biliary-Pancreatic Sciences . 2017;24(4):217–225. doi: 10.1002/jhbp.432. PubMed DOI

Zhang L., Lewis J. T., Abraham S. C., et al. Igg4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. The American Journal of Surgical Pathology . 2010;34(1):88–94. doi: 10.1097/pas.0b013e3181c6c09a. PubMed DOI

Ohara H., Nakazawa T., Kawa S., et al. Establishment of a serum igg4 cut-off value for the differential diagnosis of igg4-related sclerosing cholangitis: a Japanese cohort. Journal of Gastroenterology and Hepatology . 2013;28(7):1247–1251. doi: 10.1111/jgh.12248. PubMed DOI

Oseini A. M., Chaiteerakij R., Shire A. M., et al. Utility of serum immunoglobulin g4 in distinguishing immunoglobulin g4-associated cholangitis from cholangiocarcinoma. Hepatology . 2011;54(3):940–948. doi: 10.1002/hep.24487. PubMed DOI PMC

Graham R. P. D., Smyrk T. C., Chari S. T., Takahashi N., Zhang L. Isolated igg4-related sclerosing cholangitis: a report of 9 cases. Human Pathology . 2014;45(8):1722–1729. doi: 10.1016/j.humpath.2014.04.006. PubMed DOI

Takagi Y., Kubota K., Takayanagi T., et al. Clinical features of isolated proximal‐type immunoglobulin G4‐related sclerosing cholangitis. Digestive Endoscopy . 2019;31(4):422–430. doi: 10.1111/den.13320. PubMed DOI

Vosskuhl K., Negm A., Framke T., et al. Measurement of igg4 in bile: a new approach for the diagnosis of igg4-associated cholangiopathy. Endoscopy . 2012;44(1):48–52. doi: 10.1055/s-0030-1256872. PubMed DOI

Nakanuma Y., Zen Y. Pathology and immunopathology of immunoglobulin g4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatology Research . 2007;37(Suppl 3):S478–S486. doi: 10.1111/j.1872-034x.2007.00243.x. PubMed DOI

Nakazawa T., Ohara H., Sano H., et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointestinal Endoscopy . 2004;60(6):937–944. doi: 10.1016/s0016-5107(04)02229-1. PubMed DOI

Nishino T., Oyama H., Hashimoto E., et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. Journal of Gastroenterology . 2007;42(7):550–559. doi: 10.1007/s00535-007-2038-8. PubMed DOI

Kawakami H., Zen Y., Kuwatani M., et al. Igg4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from vater’s ampulla and the bile duct. Journal of Gastroenterology and Hepatology . 2010;25(10):1648–1655. doi: 10.1111/j.1440-1746.2010.06346.x. PubMed DOI

Kamisawa T., Tu Y., Nakajima H., Egawa N., Tsuruta K., Okamoto A. Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: a prospective study using igg4-immunostaining. World Journal of Gastroenterology . 2006;12(13):2031–2033. doi: 10.3748/wjg.v12.i13.2031. PubMed DOI PMC

Kubota K., Kato S., Akiyama T., et al. Differentiating sclerosing cholangitis caused by autoimmune pancreatitis and primary sclerosing cholangitis according to endoscopic duodenal papillary features. Gastrointestinal Endoscopy . 2008;68(6):1204–1208. doi: 10.1016/j.gie.2008.08.013. PubMed DOI

Deshpande V., Sainani N. I., Chung R. T., et al. Igg4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Modern Pathology . 2009;22(10):1287–1295. doi: 10.1038/modpathol.2009.94. PubMed DOI

Oh H.-C., Kim M.-H., Lee K. T., et al. Clinical clues to suspicion of igg4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma. Journal of Gastroenterology and Hepatology . 2010;25(12):1831–1837. doi: 10.1111/j.1440-1746.2010.06411.x. PubMed DOI

Fischer S., Trivedi P. J., Ward S., Greig P. D., Therapondos G., Hirschfield G. M. Frequency and significance of igg4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. International Journal of Experimental Pathology . 2014;95(3):209–215. doi: 10.1111/iep.12076. PubMed DOI PMC

Harada K., Shimoda S., Kimura Y., et al. Significance of immunoglobulin g4 (igg4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of igg4 reaction in cancer tissue. Hepatology . 2012;56(1):157–164. doi: 10.1002/hep.25627. PubMed DOI

Löhr J. M., Beuers U., Vujasinovic M., et al. European Guideline on IgG4‐related digestive disease - UEG and SGF evidence‐based recommendations. United European Gastroenterology Journal . 2020;8(6):637–666. doi: 10.1177/2050640620934911. PubMed DOI PMC

Kamisawa T., Shimosegawa T., Okazaki K., et al. Standard steroid treatment for autoimmune pancreatitis. Gut . 2009;58(11):1504–1507. doi: 10.1136/gut.2008.172908. PubMed DOI

Shirakashi M., Yoshifuji H., Kodama Y., et al. Factors in glucocorticoid regimens associated with treatment response and relapses of igg4-related disease: a multicentre study. Scientific Reports . 2018;8 doi: 10.1038/s41598-018-28405-x.10262 PubMed DOI PMC

Matsubayashi H., Ishiwatari H., Imai K., et al. Steroid therapy and steroid response in autoimmune pancreatitis. International Journal of Molecular Sciences . 2019;21 doi: 10.3390/ijms21010257. PubMed DOI PMC

Sah R. P., Chari S. T., Pannala R., et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology . 2010;139(1):140–148. doi: 10.1053/j.gastro.2010.03.054. PubMed DOI

Masaki Y., Shimizu H., Sato Nakamura T., et al. Igg4-related disease: diagnostic methods and therapeutic strategies in Japan. Journal of Clinical and Experimental Hematopathology . 2014;54(2):95–101. doi: 10.3960/jslrt.54.95. PubMed DOI

Kubota K., Kamisawa T., Okazaki K., et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. Journal of Gastroenterology . 2017;52(8):955–964. doi: 10.1007/s00535-016-1302-1. PubMed DOI

Khosroshahi A., Wallace Z. S., Crowe J. L., et al. International consensus guidance statement on the management and treatment of igg4-related disease. Arthritis & Rheumatology . 2015;67(7):1688–1699. doi: 10.1002/art.39132. PubMed DOI

Ebbo M., Grados A., Samson M., et al. Long-term efficacy and safety of rituximab in igg4-related disease: data from a French nationwide study of thirty-three patients. PLoS One . 2017;12(9) doi: 10.1371/journal.pone.0183844.e0183844 PubMed DOI PMC

Backhus J., Neumann C., Perkhofer L., et al. A follow-up study of a european igg4-related disease cohort treated with rituximab. Journal of Clinical Medicine . 2021;10(6):p. 1329. doi: 10.3390/jcm10061329. PubMed DOI PMC

Carruthers M. N., Topazian M. D., Khosroshahi A., et al. Rituximab for igg4-related disease: a prospective, open-label trial. Annals of the Rheumatic Diseases . 2015;74(6):1171–1177. doi: 10.1136/annrheumdis-2014-206605. PubMed DOI

Carruthers M. N., Stone J. H., Deshpande V., Khosroshahi A. Development of an igg4-rd responder index. International journal of Rheumatology . 2012;2012:7. doi: 10.1155/2012/259408.259408 PubMed DOI PMC

Lanzillotta M., Della-Torre E., Wallace Z. S., et al. Efficacy and safety of rituximab for igg4-related pancreato-biliary disease: a systematic review and meta-analysis. Pancreatology . 2021;21(7):1395–1401. doi: 10.1016/j.pan.2021.06.009. PubMed DOI

Hart P. A., Topazian M. D., Witzig T. E., et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the mayo clinic experience. Gut . 2013;62(11):1607–1615. doi: 10.1136/gutjnl-2012-302886. PubMed DOI

Bi Y., Hart P. A., Law R., et al. Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting. Pancreatology . 2016;16(3):391–396. doi: 10.1016/j.pan.2016.03.017. PubMed DOI

Iwasaki S., Kamisawa T., Koizumi S., et al. Assessment in steroid trial for igg4-related sclerosing cholangitis. Advances in Medical Sciences . 2015;60(2):211–215. doi: 10.1016/j.advms.2015.02.006. PubMed DOI